Middle East and Africa AI in Omics Studies Market

Middle East and Africa AI in Omics Studies Market Size & Forecast:

• Middle East and Africa AI in Omics Studies Market Size 2025: USD 59.73 Million 
• Middle East and Africa AI in Omics Studies Market Size 2033: USD 758.63 Million 
• Middle East and Africa AI in Omics Studies Market CAGR: 37.40%
• Middle East and Africa AI in Omics Studies Market Segments: By Type (Genomics AI, Proteomics AI, Metabolomics AI, Multi-omics Platforms, Others); By Application (Drug Discovery, Precision Medicine, Biomarker Discovery, Disease Research, Clinical Trials, Others); By End-User (Pharma Companies, Biotech Firms, Research Institutes, Healthcare Providers, Others); By Deployment (Cloud, On-premise, Hybrid, Others)

To learn more about this report,  Download Free Sample Report

Middle East and Africa AI in Omics Studies Market Summary

The Middle East and Africa AI in Omics Studies Market was valued at USD 59.73 Million in 2025. It is forecast to reach USD 758.63 Million by 2033. That is a CAGR of 37.40% over the period.

In the Middle East and Africa AI in omics studies market, it kind of acts like a computational middle layer that takes huge genomic , proteomic , and metabolomic datasets and turns them into more actionable findings for disease research, drug discovery, and precision medicine programs. Basically, in the real world, hospitals , biotech firms , and research institutes lean on AI systems to spot biomarkers, forecast treatment response, and speed up drug target validation. This also means less reliance on slow, traditional wet-lab iteration loops, which everyone knows take time.

Over the last 3 to 5 years , the market has seen a real structural change, moving away from stand alone bioinformatics tools toward integrated AI-driven multi-omics platforms. These are now being rolled out inside national genomics and precision medicine programs, in particular across the Gulf area. One big nudge behind this was the growth of population-scale genome sequencing initiatives in places like the UAE and Saudi Arabia, which were supported by health transformation agendas after 2021. With all that data, the old analytics approach simply couldn’t handle the scale and process things efficiently enough.

So, adoption is now mostly pushed by the need to translate genomic data into clinically usable decisions, and at scale too. That improves diagnostic precision, and it also helps accelerate drug development pipelines. Because of this, enterprises are putting more money into AI infrastructure, which supports faster commercialization of precision medicine offerings and helps build stronger partnerships between healthcare organizations and global life sciences technology firms.

Key Market Insights

• In the Middle East and Africa, the AI in omics studies market is kind of led by Gulf countries, and yeah they’re expected to hold about 48% share in 2025, mainly because of national genomics efforts and precision medicine programs that keep getting bigger.

• Then North Africa, it’s actually the fastest-growing slice for the Middle East and Africa AI in omics studies market forecast 2026–2033, mostly due to biotech partnerships that are expanding, plus more academic research funding, and collaborations that are starting to multiply.

• For product segmentation, bioinformatics platforms feel like the main driver, they dominate with a strong share because most teams are already using them in genomic data interpretation workflows, in a pretty routine way.

• When it comes to segments, AI-driven multi-omics integration tools are the fastest-moving area too, because healthcare systems are shifting toward predictive plus personalized treatment models, so the demand keeps climbing.
• On applications, drug discovery and precision oncology are leading overall, with more than 40% share, while biomarker identification is growing the quickest, almost like that’s where the momentum is.

• As for end users, healthcare and pharmaceutical research institutes take the largest portion, while biotech startups are showing the fastest adoption growth across emerging ecosystems and local networks.

• In terms of competition, Illumina, Thermo Fisher Scientific, IBM, Google DeepMind, Qiagen, and NVIDIA are pushing hard, basically at the point where AI and genomics start merging together.

• Also, lots of companies are expanding via AI-cloud partnerships, sequencing platform innovation and regional collaborations with sovereign healthcare programs, which makes them look more embedded.

• Illumina, in particular, strengthens its competitive position through high-throughput sequencing integration, while Thermo Fisher keeps extending clinical genomics workflow solutions on a global scale.

• And IBM along with Google DeepMind help shape leadership through advanced AI models that are focused on multi-omics pattern recognition, plus drug target discovery, you could say that’s the core edge.

What are the Key Drivers, Restraints, and Opportunities in the Middle East and Africa AI in Omics Studies Market?

Ok so the main push behind the Middle East and Africa AI in omics studies market is really the growth of national genome sequencing programs plus precision medicine efforts, especially in Gulf places like Saudi Arabia and the United Arab Emirates. A lot of this momentum came after 2020, with healthcare modernization policies, the ones that basically zoom in on early disease detection, and also population-scale genomic mapping. So now, healthcare systems are making huge multi-omics datasets, and that naturally brings along the demand for AI platforms that can handle genomic, proteomic and metabolomic information quickly, like at a clinical pace. Because of this, adoption keeps spreading across hospitals and pharmaceutical research networks. And yeah, that ends up supporting steady revenue growth for AI-enabled bioinformatics providers.

Now the biggest drag, though, is the missing standardized and interoperable data governance setup across countries in the region. In practice, omics datasets are often kept in scattered systems. Plus they follow different privacy rules, so cross-border data integration gets kind of constrained. That also lowers the efficiency of model training. This sort of structural situation raises infrastructure expenses and makes it harder to roll out scalable AI models, particularly for multinational life sciences firms that want regional datasets. Consequently, commercialization cycles can run longer than what you see in more unified regulatory contexts like North America, or parts of Europe.

A key opportunity that’s starting to show up more clearly involves sovereign AI-biobanks in the Gulf, with special focus on initiatives tied to Saudi Arabia’s Vision 2030 healthcare transformation programs. These schemes combine secure genomic data repositories with high-performance AI computing infrastructure, and they make it possible to do real-time multi-omics analysis for drug discovery and precision diagnostics.If they scale successfully, these ecosystems could help make the region a global hub for AI led biomedical invention, and in a pretty big way speed up revenue creation for the platform providers.

What Has the Impact of Artificial Intelligence Been on the Middle East and Africa AI in Omics Studies Market?

AI plus advanced digital tech is kind of reshaping omics-driven healthcare systems across the Middle East and Africa, mostly by automating genomic data processing and kind of tuning multi-omics research workflows. Practically speaking, AI platforms now streamline the sequencing pipeline management, and they can automatically sift through high-throughput genomic data, then they also weave proteomic and metabolomic datasets into one analytical framework, at least in more mature setups. Hospitals and research institutes in Gulf countries are leaning more often on cloud-based bioinformatics systems too, mostly so they can cut down on manual curation and speed up the clinical interpretation cycles.

Also, machine learning models are boosting predictive abilities in precision medicine, by picking up genetic risk signals and forecasting how disease progression may unfold over time. These setups improve drug target validation accuracy and they cut down the trial-and-error routines in pharma research. In a lot of advanced research environments AI-enabled analytics have been reported to reduce genomic analysis time by something like 30 to 50 percent, which in turn helps both research throughput and day to day operational efficiency.

Still, adoption is not fully smooth because high-quality, region-specific multi-omics datasets aren’t always readily available. That limitation tends to curb model training performance, and it also lowers predictive dependability for diverse populations. As a result data fragmentation keeps slowing large scale rollout of AI-driven omics platforms, and it also raises integration costs for healthcare providers trying to build interoperable systems across research and clinical networks.

Key Market Trends

• Gulf countries kind of shifted, from those more isolated genomics sequencing gigs to more integrated national omics programs after 2021, and honestly that really sped up the entire AI platform rollout.
• After 2023, AI-driven multi-omics adoption jumped, quite sharply, because hospitals moved away from manual bioinformatics workflows and leaned into cloud based analytics systems, like it was the obvious next step , you know.
• Illumina also expanded how much its sequencing platforms are integrated with AI pipelines, so the emphasis is more end to end data ecosystems instead of hardware first, and that’s a small change in wording but a big change in reality.
• At the same time, IBM Watson Health applications gradually drifted toward multi-omics interpretation tools, and it kind of lowered their reliance on the older, traditional statistical genomics methods, more or less.
• Pharmaceutical companies ramped up AI-assisted biomarker discovery by around 35% since 2022, mainly to compress early-stage drug development cycles, so there’s faster iteration, you get it.
• Regulatory frameworks in the UAE and Saudi Arabia moved toward data-sharing-enabled genomics policies, which made it easier to train AI models quicker across different institutions, rather than each site starting from scratch.
• In North Africa, research institutes started depending more on EU funded genomics collaborations after 2023, replacing those earlier fragmented local sequencing setups, sort of uneven before.
• Then Google DeepMind and NVIDIA expanded their AI biotech collaborations, and it feels like the competition is less about sequencing-only answers and more about computational biology platforms, and the whole stack matters more now.
• Clinical research organizations also began adopting AI omics platforms to shrink the analysis turnaround from weeks down to days, especially in oncology diagnostics workflows where time… really matters a lot.
• Since 2024, data localization requirements have been rising, and that means companies had to redo their AI models a bit, for region-specific genomic datasets and for compliance needs.

Middle East and Africa AI in Omics Studies Market Segmentation

By Type

Multi-omics platforms seem to have the leading edge, mostly because they can merge genomics, proteomics, and metabolomics into one shared analytical setup, for precision medicine programs. Genomics AI is not far behind either, helped along by national genome sequencing pushes across Gulf countries, these efforts create big datasets that still need disciplined interpretation. Proteomics and metabolomics AI look smaller for now but they are getting more attention in specific biomedical labs where people are trying to map disease mechanisms, step by step, you know.

The momentum in this area comes from moving away from single layer biological work and toward integrated multi layer modeling. Hospitals and research institutes keep asking for AI tools that connect genetic variation with protein output and metabolic pathways. When those pieces line up, diagnostic accuracy tends to improve, and clinical decision making feels less chopped up in day to day workflows. Not perfectly, but noticeably.

Looking ahead, expansion should lean more toward multi-omics platforms, since many healthcare systems are prioritizing a more complete patient picture. Developers will spend more time on interoperability between biological datasets and AI models. Meanwhile investors will likely prefer integrated platforms, because the financial upside can look stronger than what single-domain analytics tools usually provide.

By Application

Drug discovery is in the top position, mainly because pharmaceuticals are putting serious funding into AI supported target identification and molecular screening routines. Precision medicine sits next, as healthcare systems adopt genomic guided treatment planning. Biomarker discovery and disease research stay relevant at a steady pace, both in academic settings and in clinical environments too.

Growth is being pushed forward by higher demand for quicker drug development cycles , plus fewer clinical trial failures. In practice, AI systems now cut down biomarker discovery timelines by looking through huge genomic datasets in days, not months. At the same time clinical trials are leaning more and more on AI-assisted patient stratification, to boost the odds of success a bit.

Going forward , the direction points to precision medicine because healthcare providers are shifting toward individualized care models. Drug discovery should still stay dominant but there’s also growing pressure on efficiency because automation from AI is getting better. Biotech firms will keep focusing on AI tools that connect discovery, validation, and trial optimization into one smoother workflow , sort of like an integrated apparatus.

To learn more about this report,  Download Free Sample Report

By End-User

Pharmaceutical companies still lead, mostly because they can fund big scale investment in AI drug discovery and molecular modeling platforms. Healthcare providers are growing their slice too as hospitals adopt AI-based diagnostic tools and treatment planning support. Research institutes and biotech firms add steady demand , but it tends to be smaller overall.

Growth is fueled by pharmaceutical demand for faster pipeline building and lower R&D costs. Healthcare providers use AI solutions to raise diagnostic precision and improve operational efficiency across clinical workflows. Research institutes back the generation of foundational datasets and validation efforts, mainly to enable commercial applications later on.

Future expansion will kind of concentrate in healthcare providers, as clinical integration of AI omics tools accelerates kinda fast. Pharmaceutical firms will stay important buyers but shift toward platform-based partnerships instead of buying stand-alone tools. Biotech firms will gain more influence too as innovation moves quicker in more niche therapeutic areas, and that matters a lot.

By Deployment, 

Cloud deployment holds a dominant position because it offers scalability and good fit with large genomic datasets. Hybrid setups start to gain traction in regulated healthcare settings where security is a must, but people still want computational flexibility. On-premise deployment, it remains somewhat limited to institutions that have strict data sovereignty requirements, and honestly most don’t need that level.

Growth is driven by the rising volume of multi-omics data that needs high-performance cloud computing infrastructure. Hybrid models, they expand as governments push genomic data localization policies across Gulf countries. Cloud systems cut down processing time, and they also help cross-institutional collaboration for research workflows, like getting results earlier.

For the future direction, hybrid deployment models will likely be favored since they balance security with scalability and compliance needs. Cloud platforms will keep leading on innovation speed, plus integration capabilities. Buyers will prioritize flexible architectures that can support both clinical-grade tasks and research-grade workloads, all in one environment.

What are the Key Use Cases Driving the Middle East and Africa AI in Omics Studies Market?

Drug discovery still seems like the big main use case across the Middle East and Africa AI in omics studies market, kinda, mostly because pharmaceutical players want quicker target spotting and fewer clinical misses. In practice AI platforms chew through huge genomic and proteomic datasets to help compress those early research phases, and also to make molecular screening more accurate. The strongest pull is coming from pharmaceutical companies, mainly due to the pressure to speed up pipeline output, while also keeping R&D costs from climbing too much.

Precision medicine, along with biomarker discovery, keeps widening across healthcare providers and biotech companies. This is especially noticeable in Gulf hospital networks that are adopting genomic-guided treatment planning. Clinical research institutes are also using AI omics tools more and more, to help sort patients for trials, and to get therapeutic matching right more often. Overall these moves boost diagnostic precision and can make clinical trial design more efficient, not just faster.

Newer use cases are starting to show up too, like real-time disease surveillance, plus AI-guided preventive genomics that gets folded into national healthcare systems. At the same time defense-linked biomedical programs, and public health agencies, are looking into predictive population health modeling. If these efforts really scale, they could support early outbreak detection and longer-term risk forecasting, across large populations.

Which Regions are Driving the Middle East and Africa AI in Omics Studies Market Growth?

The Gulf Cooperation Council region is kind of leading the Middle East and Africa AI in omics studies market, mainly because of aggressive national genomics programs plus big healthcare digitization strategies in Saudi Arabia , and the United Arab Emirates too. Like, government-backed things such as population genome sequencing, and precision medicine frameworks, they end up producing huge datasets that really need AI-driven analysis, in practice. With strong sovereign funding, integrated hospital networks, and partnerships with global life sciences companies, you basically get a pretty structured innovation ecosystem. So, this mix of policy alignment and infrastructure scale , makes the Gulf the main hub for advanced multi-omics rollouts.

Sub-Saharan Africa looks different, sort of second-tier, and the momentum there depends more on international research collaboration and public health system strengthening rather than how much sovereign capital is being poured in. Countries like South Africa and Kenya show steady adoption of AI-driven genomics tools, mostly via university-led research programs and donor-supported healthcare efforts. Of course, economic constraints keep big infrastructure buildouts from happening quickly, but the regulatory side keeps evolving in clinical research governance, which supports a slower , gradual integration. That relative steadiness makes the region a dependable source for long-term dataset creation and clinical validation work.

North Africa is growing the fastest, mostly due to recent expansion in biomedical infrastructure and a tighter alignment with European Union research and data governance expectations. Egypt and Morocco have accelerated investments in genomics labs and digital health platforms, which improves their ability to handle big biological datasets.

Who are the Key Players in the Middle East and Africa AI in Omics Studies Market and How Do They Compete?

The Middle East and Africa AI in omics studies market kinda shows a moderately fragmented competitive setup where global life sciences leaders are still right there with cloud AI firms and genomics specialists , you know. Most incumbents keep a real advantage because they’ve built integrated sequencing plus analytics ecosystems. Then newer players try to shake things up with cloud-native AI models that cut computational cost a bit and speed up multi-omics interpretation, maybe even too fast. Overall the rivalry feels more about technical depth and data integration strength rather than price because buyers want high accuracy, scalable throughput, and strict compliance with genomic data governance rules across different healthcare systems.

In the meantime Illumina goes for technology integration leadership by blending high-throughput sequencing platforms with AI-ready data pipeline infrastructure that supports national genomics initiatives across the Gulf. The differentiation is basically tied to its end-to-end sequencing ecosystem, which helps reduce fragmentation during data generation and also improves compatibility with later AI analysis tools. They keep expanding, through partnerships with sovereign healthcare programs and regional research centers that are focused on precision medicine deployment.

Thermo Fisher Scientific builds its competitive edge via clinical workflow integration, linking lab instrumentation with AI-enabled bioinformatics platforms. Their edge is that full-stack laboratory offering which makes sample processing and data interpretation more streamlined across hospital networks. IBM and Google DeepMind, on the other hand compete with AI-first strategies, leaning into multi-omics modeling and predictive biology systems designed to shrink drug discovery timelines.

Company List

• Illumina
• Thermo Fisher
• Roche
• Agilent
• Bio-Rad
• QIAGEN
• Danaher
• PerkinElmer
• IBM
• Google
• Microsoft
• NVIDIA
• Oracle
• SAP
• Ginkgo Bioworks

Recent Development News

“In January 2025, Illumina and NVIDIA entered a strategic partnership to integrate AI-driven genomics and high-performance computing for multi-omics analysis. The collaboration enhances clinical research and drug discovery by accelerating large-scale genomic data interpretation and improving model training efficiency.https://www.rootsanalysis.com

What Strategic Insights Define the Future of the Middle East and Africa AI in Omics Studies Market?

The Middle East and Africa AI in omics studies market is kind of, basically moving toward integrated sovereign controlled precision medicine ecosystems , where national genomics programs and AI infrastructure are converging into a single healthcare intelligence system . Over the next 5 to 7 years, the expansion will be pushed by the need to operationalize population scale genomic data into sort of real-time clinical decision support, and this will be backed by cloud computing plus high performance AI models that get embedded within hospital networks. The change is speeding up too, because healthcare systems are now prioritizing predictive diagnostics and personalized treatment pathways more than the old reactive care models .

One less obvious risk is that data ownership can become more concentrated , inside a small group of cloud and genomics platform providers, and that can create dependency issues and also reduce competitive variety . As a result, smaller biotech firms might see slower innovation , since they often do not have the same reach to proprietary datasets or the computing setup.

A big emerging opportunity shows up in sovereign AI biobank ecosystems across the Gulf, where regulatory rules are still evolving, to support secure genomic data sharing for research and clinical use. Market participants should focus on building interoperable AI platforms that can connect with national biobank systems, and also follow regional data sovereignty requirements , so they can lock in longer term institutional agreements and make adoption paths more scalable.

Middle East and Africa AI in Omics Studies Market Report Segmentation

By Type 

• Genomics AI
• Proteomics AI
• Metabolomics AI
• Multi-omics Platforms
• Others

By Application 

• Drug Discovery
• Precision Medicine
• Biomarker Discovery
• Disease Research
• Clinical Trials
• Others

By End-User 

• Pharma Companies
• Biotech Firms
• Research Institutes
• Healthcare Providers
• Others

By Deployment 

• Cloud
• On-premise
• Hybrid
• Others